Press release
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market to Extend at a Significant Growth Rate During the Forecast Period (2019-32) - Estimates DelveInsight | Key Companies - POINT Biopharma (PNT2002), Merck/AstraZeneca (Lynparza/olaparib), and Nov
DelveInsight's "Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic Castration-Resistant Prostate Cancer Market Size and Share in the 7MM (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Metastatic Castration-Resistant Prostate Cancer market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Metastatic Castration-Resistant Prostate Cancer (mCRPC): An Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. However, in 6-10% of cases, cancer has spread to parts of the body farther from the prostate, such as the lungs, liver, or bones, and is known as distant or metastatic prostate cancer.
Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer. With mCRPC, cancer no longer completely responds to treatments that lower testosterone, and it is found in other parts of the body. It shows signs of growth, like a rising PSA (prostate-specific antigen), even with low testosterone levels. Metastatic CRPC is associated with a poor prognosis and reduced survival. The estimated 5-year survival rate for men with metastatic prostate cancer is around 30% compared to 100% survival in men with localized prostate cancer.
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Key Facts
- The total prevalent cases of prostate cancer in the 7MM were observed to be 6,742,000+ in 2017, which is expected to grow during the study period.
- Among the 7MM, the US accounted for the highest number of cases which were 3,170,000+ cases in 2017.
- Among the EU-5 countries, Germany had the highest diagnosed prevalent population of Prostate Cancer, followed by France and Italy. On the other hand, Spain had the lowest diagnosed prevalent population in 2017.
- Japan accounted for about 9% of the total 7MM diagnosed prevalent prostate cancer population (in 2017).
- The total number of cases of mCRPC in the 7MM was found to be 77,300+ in 2017.
- The highest cases of mCRPC were in the United States, followed by Germany in 2017.
- According to the analysis, it was found that prostate cancer is more prevalent in people of age between 65-74 years, followed by 55-64 years and 75-84 years.
Metastatic Castration-Resistant Prostate Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Metastatic Castration-Resistant Prostate Cancer market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Metastatic Castration-Resistant Prostate Cancer market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Discover How Metastatic Castration-Resistant Prostate Cancer Market will Grow by 2032:
https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Epidemiology
The epidemiology section covers detailed insights into the historical and current Metastatic Castration-Resistant Prostate Cancer patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.
The Report Covers the Metastatic Castration-Resistant Prostate Cancer (mCRPC) Epidemiology, Segmented by -
- Total Prevalent Cases of Prostate Cancer in the 7MM (2019-32)
- Total Treated Cases of Metastatic CRPC in the 7MM (2019-32)
- Age-specific Cases of Prostate Cancer in the 7MM (2019-32)
- Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM (2019-32)
- Total Diagnosed Cases of Prostate Cancer in the 7MM (2019-32)
- Total Metastatic Cases of CRPC in the 7MM (2019-32)
Get Key Insights Into the Evolving Metastatic Castration-Resistant Prostate Cancer Epidemiology Trends:
https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Castration-Resistant Prostate Cancer market or expected to be launched during the study period. The analysis covers the Metastatic Castration-Resistant Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Metastatic Castration-Resistant Prostate Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapeutics Assessment
The treatment paradigm of mCRPC, is full of competition as many of the approved therapies are already present in the market and many of the therapies are present in the pipeline for fulfilling the unmet needs in mCRPC treatment. Additionally, several key major pharma and biotech giants are working to develop new therapies for the treatment of mCRPC. Currently, Clovis Oncology is leading the therapeutics market with its Metastatic Castration-Resistant Prostate cancer drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapeutics Market Include:
- Surface Oncology
- Regeneron Pharmaceuticals
- Clovis Oncology
- AstraZeneca
- Veru Healthcare
- Hinova Pharmaceuticals
- Zenith Epigenetic
- Eli Lilly and Company
- Lantern Pharma
- Astellas Pharma
- Seagen
- Pfizer
- Progenics Pharmaceutical
- Molecular Insight Pharmaceuticals
- Bayer
- Accutar Biotechnology Inc
- Hinova Pharmaceuticals
- Taiho Oncology, Inc.
- Forma Therapeutics, Inc.
- Dizal Pharmaceuticals
- Amgen
And Many Others
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapies Covered in the Report Include:
- SRF617: Surface Oncology
- Rucaparib: Clovis Oncology
- HP518: Hinova Pharmaceuticals
- Proxalutamide (GT0918): Suzhou Kintor Pharmaceutical
- Opdivo (nivolumab): Bristol-Myers Squibb
- 177Lu-PSMA-617: Novartis
- HC-1119: Hinova Pharmaceuticals
- EPI-7386: ESSA Pharmaceuticals
- ODM-208: Orion Pharma
- Sacituzumab Govitecan (IMMU-132): Immunomedics
- Keytruda (Pembrolizumab/MK-3475): Merck Sharp & Dohme
- Ipatasertib (RG7440): Hoffmann-La Roche
- Talazoparib: Pfizer/Astellas Pharma
- Capivasertib (AZD5363): AstraZeneca
- AZD4635: AstraZeneca
- Abemaciclib (LY2835219): Eli Lilly and Company
- Niraparib: Janssen Research & Development
- Onvansertib: Cardiff Oncology
- LAE001: Laekna Therapeutics
And Many More
Learn More About the Emerging Therapies & Key Companies in the Metastatic Castration-Resistant Prostate Cancer Therapeutics Market:
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic Castration-Resistant Prostate Cancer Competitive Intelligence Analysis
4. Metastatic Castration-Resistant Prostate Cancer Market Overview at a Glance
5. Metastatic Castration-Resistant Prostate Cancer Background and Overview
6. Metastatic Castration-Resistant Prostate Cancer Patient Journey
7. Metastatic Castration-Resistant Prostate Cancer Epidemiology and Patient Population
8. Metastatic Castration-Resistant Prostate Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Castration-Resistant Prostate Cancer Unmet Needs
10. Key Endpoints of Metastatic Castration-Resistant Prostate Cancer Treatment
11. Metastatic Castration-Resistant Prostate Cancer Marketed Products
12. Metastatic Castration-Resistant Prostate Cancer Emerging Therapies
13. Metastatic Castration-Resistant Prostate Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Castration-Resistant Prostate Cancer Market Outlook (7 major markets)
16. Metastatic Castration-Resistant Prostate Cancer Access and Reimbursement Overview
17. KOL Views on the Metastatic Castration-Resistant Prostate Cancer Market.
18. Metastatic Castration-Resistant Prostate Cancer Market Drivers
19. Metastatic Castration-Resistant Prostate Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Trending Market Research Reports 2032 | DelveInsight
Technical Due Diligence Firms- https://www.delveinsight.com/consulting/due-diligence-services
Vital Sign Monitors Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Anastomosis Device Market- https://www.delveinsight.com/report-store/anastomotic-leak-devices-market
Asperger Syndrome Market- https://www.delveinsight.com/report-store/asperger-syndrome-market
B-Cell Maturation Antigen Targeted Therapies Market- https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market
UK Healthcare Report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
Oncolytic Virus Cancer Therapy Pipeline- https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021
Shingles Market- https://www.delveinsight.com/report-store/shingles-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market to Extend at a Significant Growth Rate During the Forecast Period (2019-32) - Estimates DelveInsight | Key Companies - POINT Biopharma (PNT2002), Merck/AstraZeneca (Lynparza/olaparib), and Nov here
News-ID: 2897512 • Views: …
More Releases from DelveInsight Business Research
Global General Surgery Devices Market is expected to grow at a CAGR of 6.3% by 2 …
General Surgery Devices Market Overview
The Global General Surgery Devices Market is projected to grow at a CAGR of 6.34% from 2025 to 2032, driven by the rising burden of chronic diseases, increasing surgical interventions, and the adoption of robotic-assisted and minimally invasive techniques. Covering instruments such as handheld tools, electrosurgical devices, laparoscopic systems, wound closure products, and disposables, these devices play a critical role in diverse procedures, including orthopedic, cardiovascular,…
Intratumoral Cancer therapies Market Outlook 2034 - Clinical Trials, Market Size …
Intratumoral Cancer Market Summary
Intratumoral cancer therapies involve direct delivery into tumors, enabling localized targeting with minimal damage to surrounding tissue. Within the 7MM, non-melanoma cancers represent the largest share of cases and are expected to rise at ~2% annually, while in the US, breast cancer accounts for about 30% of cases with a growing incidence rate for intratumoral therapies. Currently, IMLYGIC is the only FDA-approved intratumoral therapy for melanoma, holding…
Bispecific and Trispecific Antibodies Market Projected to Experience Significant …
Bispecific antibodies represent an innovative class of therapies designed to address complex diseases by simultaneously binding two targets with a single molecule. Most currently approved bispecifics are for oncology, particularly multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Beyond oncology, only HEMLIBRA and VABYSMO are approved for conditions such as hemophilia A, wet age-related macular degeneration, and diabetic macular edema, while KIMMTRAK is approved for uveal melanoma. The pipeline remains…
Narcolepsy Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Update …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Narcolepsy pipeline constitutes 10+ key companies continuously working towards developing 12+ Narcolepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Prostate
The 3D Urology and Prostate Clinics Introduces Innovative Natural and Targeted P …
The 3D Urology and Prostate Clinics introduces its innovative 3D targeted injection therapies, offering effective, natural solutions for various prostate conditions including prostatitis, enlarged prostate, and prostate cancer.
Renowned for its pioneering approach to prostate health, The 3D Urology and Prostate Clinics is bringing renewed hope to patients worldwide suffering from various prostate diseases. Utilizing advanced diagnostic techniques and a unique targeted injection method, the clinics offer specialized treatments that focus…
The 3D Urology and Prostate Clinics Introduces Advanced 3D Prostate Targeted Tre …
The 3D Urology and Prostate Clinics announces its latest breakthrough in targeted prostate treatment, offering a revolutionary approach to prostate cancer and other prostate-related conditions.
The 3D Urology and Prostate Clinics, renowned for its advanced techniques in prostate health, is proud to present its groundbreaking 3D prostate Targeted Treatment, a comprehensive and non-invasive solution for men suffering from prostate conditions. The clinic's innovative treatment is designed to target the root causes…
The 3D Urology and Prostate Clinics Unveil Innovative 3D Prostate Targeted Treat …
The 3D Urology and Prostate Clinics introduce their groundbreaking 3D prostate targeted treatment, offering a non-invasive solution for prostate health issues.
The 3D Urology and Prostate Clinics, renowned for their specialized treatments in prostate health, are proud to unveil their innovative 3D prostate targeted treatment. This cutting-edge therapy provides a non-invasive, highly effective solution for prostate-related conditions, offering patients a new path to recovery and well-being.Image: https://i.imgur.com/NCfbb6S.jpg
At the heart of this…
The 3D Urology and Prostate Clinics Unveils Advanced 3D prostate Targeted Treatm …
The 3D Urology and Prostate Clinics is at the forefront of prostate care, offering the advanced 3D Targeted Therapy as a precise and effective treatment solution.
The 3D Urology and Prostate Clinics is proud to announce its revolutionary 3D prostate Targeted Treatment [http://www.3dprostatecure.com/page.php?cata_id=19], setting a new standard in prostate care. This highly advanced treatment option utilizes cutting-edge technology to deliver focused treatment, minimizing side effects and enhancing recovery for patients. Men…
3D Prostate Cure: Revolutionizing Prostate Treatment with Targeted Therapy
This news release highlights the 3D Urology and Prostate Clinics' innovative approach to prostate treatment using 3D Targeted Therapy, offering a safe and effective alternative to traditional methods.
As a global leader in men's health, The 3D Urology and Prostate Clinics is committed to providing cutting-edge treatments for various prostate conditions. The clinic is proud to announce its revolutionary 3D Targeted Therapy, offering a new standard in prostate care.
This innovative therapy…
The 3D Urology and Prostate Clinics Enhance Prostate Health with Advanced 3D Pro …
The 3D Urology and Prostate Clinics are revolutionizing prostate care with their comprehensive treatments, including the 3D prostate Targeted Treatment and 3D Targeted Therapy, developed to ensure effective, non-surgical solutions for prostate health issues.
At the forefront of prostate health, The 3D Urology and Prostate Clinics are excited to offer innovative treatments such as the 3D prostate Targeted Treatment and 3D Targeted Therapy. These treatments are part of the clinic's commitment…
